Navigation Links
Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent

t Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com .

CONTACT: Media, Karin Bauer Aranaz, +1-415-859-3414, , Nicole Osmer, +1-650-454-0504, , or Financial, Tina Ventura, +1-847-772-5006, , all of Abbott karin.baueraranaz@av.abbott.com nicole.osmer@av.abbott.com tina.ventura@abbott.com

Web site: http://www.abbott.com/

Ticker Symbol: (:ABT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/20/2009)...CK, Mass. and LONDON, Nov. 20 /PRNewswire-FirstCal... today announced that it has received 510(k) clear...DA) and CE Mark approval to market its WallFlex...nt of malignant esophageal strictures (obstruction... non-resectable esophageal cancer. ,, (Photo: ...
(Date:11/20/2009)...IN LAKES, N.J., Nov. 20 ...today announced the completion of its acquisition ...mpany that develops and manufactures molecular dia...May 2009, BD and HandyLab announced an exclusive a...ular assays on the HandyLab Jaguar(TM) platform, t...
(Date:11/19/2009)...INGHAM, Ala., Nov. 19 Bi...y announced the pricing of a public offering of 5,...are, resulting in gross proceeds of $48.75 million... pursuant to an effective shelf registration state...ange Commission. BioCryst has also granted the un...
Breaking Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Experimental Urine Test Spots Appendicitis 49786 1Experimental Urine Test Spots Appendicitis 49786 2YM BIOSCIENCES REPORTS DAIICHI SANKYO ENROLLS FIRST PATIENTS IN PHASE II FIRST LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 12750 1YM BIOSCIENCES REPORTS DAIICHI SANKYO ENROLLS FIRST PATIENTS IN PHASE II FIRST LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 12750 2YM BIOSCIENCES REPORTS DAIICHI SANKYO ENROLLS FIRST PATIENTS IN PHASE II FIRST LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 12750 3YM BIOSCIENCES REPORTS DAIICHI SANKYO ENROLLS FIRST PATIENTS IN PHASE II FIRST LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 12750 4YM BIOSCIENCES REPORTS DAIICHI SANKYO ENROLLS FIRST PATIENTS IN PHASE II FIRST LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 12750 5Capital BlueCross Products Receive Excellent National Accreditation 49781 1Capital BlueCross Products Receive Excellent National Accreditation 49781 2
...t. 28 Premier Research Group Limited,the internat...ded the Good,Clinical Practice Journal (GCPj) Awar... its Global Phase 2 Chronic Myeloid Leukemia team.... recognizes, celebrates, and rewards,corporate and... "Clinical Research Team of the Year" award honors...
... Leads Investment in Lutonix to Fund Human Clinica...ay announced the,close of a $20 million Series B f...M.D. and Lixiao Wang PhD, Lutonix is a medical dev...ialization of drug coated balloon,angioplasty tech...y and,peripheral artery stenosis caused by atheros...
Other Medicine Technology:Premier Research Honored as 'Clinical Research Team of the Year' at 2008 GCPj Awards 2Lutonix Inc. Announces $20 Million Series B Financing 2Lutonix Inc. Announces $20 Million Series B Financing 3
(Date:11/20/2009)...USNewswire/ -- The American Academy of Actuarie ... legislation released this week to contain stronge... coverage mandate. The actuaries said that an effe...e selection stemming from more restrictive issue a... individual mandate language should be strengthene...
(Date:11/20/2009)...ssmen in Competitive Re-election Battles Could Be ... Washington, DC (Vocus) November 20...election next year in races deemed to be competiti...ret voting for House Speaker Nancy Pelosi’s ...ternational/ O’Leary Report poll. (The Pol...
(Date:11/20/2009)...FirstCall/ -- Centene Corporation (NYSE: CNC )...of America Merrill Lynch 2009 Credit Conference, t...Hotel Times Square in New York City. ,, Centene... Eastern Time. Investors and other interested part...presentation at: http://www.veracast.com/webcasts...
(Date:11/20/2009)...wswire/ -- The following is a statement by Charles...re Association: ,, "The Nevada Health Care Asso... Leader Harry Reid for his leadership in taking ou...ng every Nevada seniors, ongoing access to quality...d viability of our state,s vital frontline workfor...
(Date:11/20/2009)...used for embalming in the funeral industry were as...oid leukemia, according to a new study published o...Cancer Institute . , Previous studies have shown...ncies and brain cancer in anatomists, pathologists...ve worked with formaldehyde. , For this study,...
Breaking Medicine News(10 mins):Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2
...meday yield therapies to restore sight, experts su...s) -- A gene that plays a major role in two forms ...nternational team of researchers. , The discovery ...nal metabolic disease pathway that might be crucia...
...ect care patients might get, experts warn , ...ercent of those training to be dietitians have pos...bese, and the rest are moderately biased against t...ive attitudes toward obese patients that may have ...
... Phoenix Health Systems, a national provider of he...lting and business process solutions, announced to...o offer hospitals and other healthcare organizatio...goes beyond regulated compliance requirements to m...
...rope and Asia to Realize New Executive Leadership ...9: Tokyo Stock Exchange), a leading medical diagn...rmation systems developer, today announced executi...n to Sysmex Corporate after a six-year tenure in t...
...new study headed by Dr. Tom Feasby, Dean of UCalga...lags behind other countries in the number of diagn...nly solution to long wait times. The study,s autho...he current system. We hope this research will help...
...ch 5, 2009) -- Two highly lethal viruses that have...loroquine, an established drug used to prevent and...tudy by researchers at Weill Cornell Medical Colle...e two henipaviruses that are the subject of the st...
Other Medicine News:Health News:Retinal Gene Is Linked to Childhood Blindness 2Health News:Bias Against Obesity Is Found Among Future Dietitians 2Health News:Bias Against Obesity Is Found Among Future Dietitians 3Health News:Phoenix Health Systems Launches Total Security Program for the Healthcare Industry 2Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Lack of strategies to manage MRI wait lists a key reason for excessive wait times 2Health News:Drug blocks 2 of world's deadliest emerging viruses 2Health News:Drug blocks 2 of world's deadliest emerging viruses 3
Illiterate 20' Test Chart
PowerLab/8SP
Worth 4 Dot Test
Kindergarten 20' Test - BC1263
Medicine Products: